PLEASANTON, Calif.--The Cooper Companies’ (NYSE: COO) CooperVision contact lens division saw its revenues climb by 12 percent, to $205.5 million, in the company’s first quarter ended Jan. 31.

Broken down by product, CooperVision’s specialty lens revenue (toric, multifocal and cosmetic) was $86.7 million in Q1, up 12 percent. Sales of toric lenses reached $70.5 million, up 11 percent; multifocal lens sales were $12.7 million in the period, up 24 percent.

Revenues from CooperVision’s Proclear products were $51.6 million, up 34 percent from last year’s first quarter. Sales of single-use CLs rose 41 percent, to $36.2 million, while sales of the company’s Biofinity contact lens fell to $9.1 million, vs. $9.8 million in the prior year’s Q1.

According to Robert Weiss, the parent company’s chief executive officer, “At [CooperVision], revenues were strong in all geographic markets and we outpaced market growth. We are clearly seeing a revival of CVI’s historic revenue growth and share-gain patterns.”

The Cooper Companies is now projecting full-year 2008 sales of from $895 million to $930 million, up from previous projections of sales in the $875 million to $920 million range. ■